Elamipretide — Safety, Research, Risks & Legal Status

Not medical advice. Elamipretide is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	SS-31, MTP-131, Szeto-Schiller peptide, mitochondrial targeting peptide
Category	Peptide
cell_penetrating	True
amino_acid_count	4
target	Inner mitochondrial membrane
US legal status	Not FDA-approved; investigational peptide for mitochondrial diseases and age-related conditions. In clinical trials for Barth syndrome and other genetic mitochondrial disorders. Restricted to clinical trial or compassionate use programs; not available for general purchase.

What is Elamipretide?

A 4-amino-acid cell-penetrating peptide (SS-31 or D-Arg-2'-6'-dimethyltyrosine-L-lysine-L-phenylalanine) that targets mitochondria. Localizes to inner mitochondrial membrane and supports cardiolipin structure, restores electron transport chain function, and reduces reactive oxygen species production.

How it works

Elamipretide penetrates cell membranes and localizes to the inner mitochondrial membrane. It stabilizes cardiolipin and restores electron transport chain Complex I-IV function, reducing ROS.

Background & history

Developed by Stealth BioTherapeutics in the 1990s as a mitochondrial-targeting peptide. Advanced to Phase 2 trials for Barth syndrome and other mitochondrial disorders; no FDA approval yet.

What the research says

Phase 2 clinical trials show elamipretide improves cardiac and muscular function in Barth syndrome patients, a rare genetic mitochondrial disorder. Smaller studies suggest potential for heart failure and other mitochondrial diseases. Mechanism is well-established in animal models and cell culture. Human clinical evidence remains limited to specific disease populations; general anti-aging efficacy is unproven.

Reported effects

Studied for mitochondrial function restoration in disease states
Reported to improve cardiac and muscular function in Barth syndrome
Research suggests benefits for heart failure and mitochondrial dysfunction
Limited human clinical data; primary focus on genetic disease
General anti-aging efficacy in healthy humans unproven

Dosing & administration (informational)

Phase 2 trials used 0.5-2 mg/kg intravenously; oral dosing not feasible. Optimal dosing for disease or anti-aging unestablished.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Generally well-tolerated in clinical trials; adverse events mild to moderate
Injectable peptide; pharmaceutical-grade manufacturing essential
Endotoxin and sterility testing critical due to direct mitochondrial targeting
Long-term safety beyond clinical trial durations unknown
Cell-penetrating peptides may have unpredictable systemic effects

Drug & supplement interactions

Potential interaction with other mitochondrial-targeting compounds
Unknown interaction with CoQ10 or other mitochondrial supplements
Possible interaction with antioxidant therapies
Interaction with cardiolipin-modulating agents uncertain

Who should avoid it

Non-pharmaceutical or unverified sources
Use without clinical oversight in rare mitochondrial disorders
Concurrent untested mitochondrial-targeting compounds
Use in severe liver or kidney disease without specialist evaluation

How it is commonly combined

Elamipretide combined with CoQ10, other mitochondrial peptides, or antioxidants is theoretical; clinical safety data absent.

Legal & regulatory. Not FDA-approved; investigational peptide for mitochondrial diseases and age-related conditions. In clinical trials for Barth syndrome and other genetic mitochondrial disorders. Restricted to clinical trial or compassionate use programs; not available for general purchase.

Quality & harm reduction

P
h
a
r
m
a
c
e
u
t
i
c
a
l
-
g
r
a
d
e
s
y
n
t
h
e
s
i
s
a
n
d
t
h
i
r
d
-
p
a
r
t
y
C
O
A
m
a
n
d
a
t
o
r
y
.
E
n
d
o
t
o
x
i
n
t
e
s
t
i
n
g
b
e
l
o
w
0
.
1
E
U
/
m
L
r
e
q
u
i
r
e
d
;
m
i
t
o
c
h
o
n
d
r
i
a
l
u
p
t
a
k
e
i
n
c
r
e
a
s
e
s
s
y
s
t
e
m
i
c
r
i
s
k
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Is Elamipretide approved by the FDA?

Not yet for general use. Elamipretide is in clinical trials for Barth syndrome and other mitochondrial diseases. It may become available through compassionate use programs before formal approval.

How does Elamipretide work?

It penetrates cells and localizes to the inner mitochondrial membrane, where it stabilizes cardiolipin and restores electron transport chain function, reducing energy-producing deficits.

Can Elamipretide reverse mitochondrial aging?

In genetic mitochondrial diseases, it shows promise. General anti-aging use in healthy mitochondria is speculative; no human evidence exists.

What are the main side effects?

In clinical trials, side effects have been mild, mostly mild injection site reactions or transient elevated liver enzymes. Serious adverse events have been rare.

Is Elamipretide available outside clinical trials?

Not legally. Elamipretide is restricted to clinical trial or compassionate use programs in most jurisdictions. It is not sold commercially.

References & further reading

M
i
t
o
c
h
o
n
d
r
i
a
l
d
i
s
e
a
s
e
a
n
d
c
a
r
d
i
o
l
o
g
y
j
o
u
r
n
a
l
s
;
P
h
a
s
e
2
c
l
i
n
i
c
a
l
t
r
i
a
l
l
i
t
e
r
a
t
u
r
e
;
S
z
e
t
o
-
S
c
h
i
l
l
e
r
p
e
p
t
i
d
e
r
e
s
e
a
r
c
h
.